USD/JPY remains stable near yearly highs as geopolitical risks, Fed policy loom
USD/JPY trades around 158.90 on Thursday at the time of writing, showing little change on the day. The pair remains close to its yearly highs, supported by a relatively firm US Dollar (USD) despite a tense geopolitical backdrop and growing expectations that Japan may gradually normalize its monetary policy.
Geopolitical developments in the Middle East are drawing strong market attention. Iran has launched what it described as its most intense operation since the beginning of the war, notably attempting to disrupt traffic through the Strait of Hormuz, a crucial passage for global Oil flows. At the same time, the Israel Defense Forces announced a wide-scale wave of strikes targeting Hezbollah infrastructure. In this environment, traders are closely monitoring the evolution of the conflict, as any escalation involving Iran, its regional neighbors, the United States (US) or Israel could strengthen demand for safe-haven assets such as the Japanese Yen (JPY) and weigh on USD/JPY in the near term.
On the macroeconomic front, data released Wednesday by the Bureau of Labor Statistics showed that the US Consumer Price Index (CPI) rose 0.3% MoM in February, compared with 0.2% previously, in line with market expectations. Core inflation, which excludes volatile food and energy prices, increased by 0.2% MoM after a 0.3% rise previously, also matching forecasts. Market participants largely looked through the report and instead focused on rising Oil prices, which could push headline inflation higher in the coming months.
Markets now widely expect the Federal Reserve (Fed) to keep interest rates unchanged at its upcoming policy meeting on March 18. However, the outlook for energy-driven inflation and persistent geopolitical risks continues to provide support for the US Dollar.
Several financial institutions are urging caution at current levels. Analysts at DBS note that the pair is testing an important resistance zone around 159-160, while the Bank of Japan (BoJ) could deliver a hawkish hold at its March 19 meeting as it continues its path toward policy normalization. According to DBS, a diplomatic de-escalation in the Middle East, potentially linked to upcoming discussions between the US and China, could lower energy prices and weaken the current fundamental support for USD/JPY.
Meanwhile, analysts at MUFG argue that rising energy prices represent a negative terms-of-trade shock for Japan, which may lead authorities to tolerate a weaker JPY in the near term. This situation could raise the threshold for foreign exchange intervention, even as expectations grow that the Bank of Japan could deliver another rate hike as soon as April.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
